|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Azzoli CG, Temin S and Giaccone G: 2011
Focused update of 2009 American society of clinical oncology
clinical practice guideline update on chemotherapy for stage IV
non-small-cell lung cancer. J Oncol Pract. 8:63–66. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ettinger DS, Akerley W, Borqhaei H, Chang
AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R,
Grannis FW Jr, et al: Non-small cell lung cancer, version 2.2013. J
Natl Compr Canc Netw. 11:645–653. 2013.PubMed/NCBI
|
|
4
|
Rigas JR: Taxane-platinum combinations in
advanced non-small cell lung cancer: A review. Oncologist. 9(Suppl
2): S16–S23. 2004. View Article : Google Scholar
|
|
5
|
Davis A, Tinker AV and Friedlander M:
‘Platinum resistant’ ovarian cancer: What is it, who to treat and
how to measure benefit? Gynecol Oncol. 133:624–631. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Torigoe T, Izumi H, Ishiguchi H, et al:
Cisplatin resistance and transcription factors. Curr Med Chem
Anticancer Agents. 5:15–27. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gao L, Liu G, Ma J, Wang X, Wang F, Wang H
and Sun J: Paclitaxel nanosuspension coated with P-gp inhibitory
surfactants: II. Ability to reverse the drug-resistance of H460
human lung cancer cells. Colloids Surf B Biointerfaces.
117:122–127. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yamagishi T, Sahni S, Sharp DM, Arvind A,
Jansson PJ and Richardson DR: P-glycoprotein mediates drug
resistance via a novel mechanism involving lysosomal sequestration.
J Biol Chem. 288:31761–31771. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cavallo F, Feldman DR and Barchi M:
Revisiting DNA damage repair, p53-mediated apoptosis and cisplatin
sensitivity in germ cell tumors. Int J Dev Biol. 57:273–280. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang M, Shan X, Zhou X, Qiu T, Zhu W, Ding
Y, Shu Y and Liu P: miR-1271 regulates cisplatin resistance of
human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR and
BCL2. Anticancer Agents Med Chem. 14:884–891. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang G, Reed E and Li QQ: Molecular basis
of cellular response to cisplatin chemotherapy in non-small cell
lung cancer (Review). Oncol Rep. 12:955–965. 2004.PubMed/NCBI
|
|
12
|
Ota K: Nedaplatin. Gan To Kagaku Ryoho.
23:379–387. 1996.(In Japanese). PubMed/NCBI
|
|
13
|
Jin J, Xu X, Wang F, Yan G, Liu J, Lu W,
Li X, Tucker SJ, Zhong B, Cao Z and Wang D: Second-line combination
chemotherapy with docetaxel and nedaplatin for cisplatin-pretreated
refractory metastatic/recurrent esophageal squamous cell carcinoma.
J Thorac Oncol. 4:1017–1021. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li CH, Liu MY, Liu W, Li DD and Cai L:
Randomized control study of nedaplatin or cisplatin concomitant
with other chemotherapy in the treatment of advanced non-small cell
lung cancer. Asian Pac J Cancer Prev. 15:731–736. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sharom FJ: Complex interplay between the
P-glycoprotein multidrug efflux pump and the membrane: Its role in
modulating protein function. Front Oncol. 4:412014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fu D: Where is it and how does it get
There-intracellular localization and traffic of P-glycoprotein.
Front Oncol. 3:3212013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vaughan CA, Singh S, Windle B, Yeudall WA,
Frum R, Grossman SR, Deb SP and Deb S: Gain-of-function activity of
mutant p53 in lung cancer through up-regulation of receptor protein
tyrosine kinase axl. Genes Cancer. 3:491–502. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wu ZZ, Sun NK and Chao CC: Knockdown of
CITED2 using short-hairpin RNA sensitizes cancer cells to cisplatin
through stabilization of p53 and enhancement of p53-dependent
apoptosis. J Cell Physiol. 226:2415–2428. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bazzi H and Anderson KV: Acentriolar
mitosis activates a p53-dependent apoptosis pathway in the mouse
embryo. Proc Natl Acad Sci USA. 111:E1491–E1500. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Oren M and Rotter V: Mutant p53
gain-of-function in cancer. Cold Spring Harb Perspect Biol.
2:a0011072010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Perrone F, Bossi P, Cortelazzi B, Locati
L, Quattrone P, Pierotti MA, Pilotti S and Licitra L: TP53
mutations and pathologic complete response to neoadjuvant cisplatin
and fluorouracil chemotherapy in resected oral cavity squamous cell
carcinoma. J Clin Oncol. 28:761–766. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bossi G, Lapi E, Strano S, Rinaldo C,
Blandino G and Sacchi A: Mutant p53 gain of function: Reduction of
tumor malignancy of human cancer cell lines through abrogation of
mutant p53 expression. Oncogene. 25:304–309. 2006.PubMed/NCBI
|
|
23
|
Tian B, Liu J, Liu B, Dong Y, Liu J, Song
Y and Sun Z: p53 Suppresses lung resistance-related protein
expression through Y-box binding protein 1 in the MCF-7 breast
tumor cell line. J Cell Physiol. 226:3433–3441. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cuddihy AR, Jalali F, Coackley C and
Bristow RG: WTp53 induction does not override MTp53 chemoresistance
and radioresistance due to gain-of-function in lung cancer cells.
Mol Cancer Ther. 7:980–992. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chung SK, Zhu S, Xu Y and Fu X: Functional
analysis of the acetylation of human p53 in DNA damage responses.
Protein Cell. 5:544–551. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Podolski-Renić A, Jadranin M, Stanković T,
Banković J, Stojković S, Chiourea M, Aljančić I, Vajs V, Tešević V,
Ruždijić S, et al: Molecular and cytogenetic changes in multi-drug
resistant cancer cells and their influence on new compounds
testing. Cancer Chemother Pharmacol. 72:683–697. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pore MM, Hiltermann TJ and Kruyt FA:
Targeting apoptosis pathways in lung cancer. Cancer Lett.
332:359–368. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kumar Biswas S, Huang J, Persaud S and
Basu A: Down-regulation of Bcl-2 is associated with cisplatin
resistance in human small cell lung cancer H69 cells. Mol Cancer
Ther. 3:327–334. 2004.PubMed/NCBI
|
|
29
|
Gumulec J, Balvan J, Sztalmachova M,
Raudenska M, Dvorakova V, Knopfova L, Polanska H, Hudcova K,
Ruttkay-Nedecky B, Babula P, et al: Cisplatin-resistant prostate
cancer model: Differences in antioxidant system, apoptosis and cell
cycle. Int J Oncol. 44:923–933. 2014.PubMed/NCBI
|
|
30
|
Akutsu Y, Shuto K, Kono T, Uesato M,
Hoshino I, Shiratori T, Miyazawa Y, Isozaki Y, Akanuma N and
Matsubara H: A phase 1/11 study of second-line chemotherapy with
fractionated docetaxel and nedaplatin for 5-FU/cisplatin-resistant
esophageal squamous cell carcinoma. Hepatogastroenterology.
59:2095–2098. 2012.PubMed/NCBI
|
|
31
|
Yoshioka T, Sakayori M, Kato S, Chiba N,
Miyazaki S, Nemoto K, Shibata H, Shimodaira H, Ohtsuka K, Kakudo Y,
et al: Dose escalation study of docetaxel and nedaplatin in
patients with relapsed or refractory squamous cell carcinoma of the
esophagus pretreated using cisplatin, 5-fluorouracil and radiation.
Int J Clin Oncol. 11:454–460. 2006. View Article : Google Scholar : PubMed/NCBI
|
